According to our latest market research study on “Global Enteral and Parenteral Medical Nutrition Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Indication, Nutrition Type, Form, Product Type, Route of Administration, Age Group, and Distribution Channel,” the market is expected to grow from US$ 17,343.46 million in 2022 to US$ 25,476.86 million by 2028; it is estimated to grow at a CAGR 6.8% during 2023–2028. Factors driving the market's growth are rise in prevalence of gastrointestinal diseases and increasing cases of malnutrition and premature births. 
         
Companies operating in the enteral and parenteral medical nutrition market constantly focus on strategic developments such as collaborations, expansions, agreements, partnerships, and new product launches, which help them improve their sales, expand their geographic reach, and enhance their capacities to cater to a greater than existing customer base. A few of the noteworthy developments in the enteral and parenteral medical nutrition market are mentioned below:

• In January 2023, Nutricia launched Fortimel PlantBased Energy, its first plant-based, ready-to-drink, oral nutritional supplement. The product is specifically formulated to fulfill the nutritional needs of malnourished people or people at risk of malnutrition due to illness. With the launch of Fortimel, the company builds on Danone's (parent company) expertise in plant nutrition to expand its Fortimel portfolio. The new product is available in the Netherlands, Denmark, Norway, Spain, Finland, and the Czech Republic.
• In June 2022, Nestle Health Science acquired The Better Health Company (TBHC) from CDH Investments and TBHC founding shareholders. The acquisition includes the GO Healthy brand. along with its vitamin and supplement lineups; the Manuka honey brand Egmont; and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins, minerals, and supplements. The acquisition helped Nestle Health Science strengthen and expand its presence in New Zealand, Australia, and other Asia Pacific countries.
• In May 2022, Nestle Health Science acquired Puravida, a premium Brazilian nutrition and healthy lifestyle brand. Puravida's products complement Nestle’s portfolio. Vitamins, minerals, and supplements are part of a growing segment of Nestle and with this acquisition, the company has the ability to expand its range of brands in different categories and reach a broader range of consumers and patients with improved reliable, nutritious, and high-quality products.
• In March 2022, Vygon (a specialist single-use medical devices group) acquired Macatt Medica (a distribution company located in Peru). Macatt Medica distributes most of Vygon’s products in Peru, including a range of enteral nutrition products. With the acquisition, Macatt Medica became a fully owned subsidiary of Vygon, supporting the latter’s operations in South America.
• In March 2022, Fresenius Kabi’s SMOFlipid lipid injectable emulsion received US Food and Drug Administration (FDA) approval. The emulsion is used to provide parenteral nutrition to pediatric patients, including term and preterm neonates, which makes it the first and only four-oil lipid emulsion for pediatric patients requiring parenteral nutrition.
• In November 2021, Abbott launched Similac 360 Total Care with an exclusive blend of five human milk oligosaccharides (HMO). It is the US’ first and only infant formula with a blend of five different prebiotic HMOs (only found together in breast milk). Similac 360 Total Care is developed to provide nutrition to support whole health and development in babies, including the development of the immune system, digestive system, and brain.
• In September 2021, Abbott introduced plant-based protein and organic food ingredients—PediaSure Harvest and Ensure Harvest—for people relying on feeding tubes. Harvest products can be used as sole-source nutrition or a supplement to satisfy daily nutrition requirements.
• In December 2020, Abbott launched the Pedialyte Hydration Solution, a new formulation designed with key nutrients to support immune health. Pedialyte with immune support includes prebiotics, vitamin B12, vitamin C, vitamin E, and zinc, specifically chosen for their importance in the development and improvement of the immune system.
• In October 2020, Nutricia (part of Danone) acquired Real Food Blends. The company helps contribute to the real food blends mission and portfolio by bringing more unique and nutritious choices to children and adults dependent on feeding tubes. 

Therefore, introducing products such as ready-to-drink and ready-to-use nutritional supplements; the development of innovative products targeting various health issues; and strategic moves such as expansions and acquisitions allow companies in the enteral and parenteral medical nutrition market size to create new or improved products and new business to remain competitive in the market. Thus, such strategic growth initiatives create significant growth opportunities in the market.

Based on form, the global enteral and parenteral medical nutrition market is segmented into liquid, powder, and semi-solid. The liquid segment held the largest share of the market in 2022 and powder segment is anticipated to register the highest CAGR of 7.2% in the market during the forecast period. Medical nutrition can be of two types—flavored and non-flavored. NUTRISOURCE is an enteral medical nutrition powder offered by Nestle. It provides 3 grams of soluble fiber from 100% partially hydrolyzed guar gum (PHGG) to support digestive health and normal bowel function. Another product named GLUTASOLVE from Nestle contains supplemental L-glutamine, an amino acid that is an important fuel source for the digestive tract cells. GLUTASOLVE is designed for conditions associated with gastrointestinal injury or disease. Moreover, consumers can order customized enteral medical products as per their specifications or prescribed by healthcare professionals.

Handling parenteral powder products requires proper control, which inherently generates particulates when transferred to the patient’s body. Companies focus on developing parenteral powder products that can be filled quickly in an aseptic environment. For instance, Evonik improved its powder transfer process for parenteral drug products without compromising efficiency or safety. Improvement in the product quality of powder parenteral nutrition is fueling segmental growth. 

The patients infected by COVID-19 have acute respiratory distress syndrome and may need urgent respiratory and hemodynamic support in the intensive care unit (ICU). According to the European Journal of Clinical Nutrition study, globally, around 53% of elderly patients hospitalized due to COVID-19 were malnourished. The study also recommended nutritional support be integrated into the global management of COVID-19. Enteral nutrition can be delivered to ventilated patients with COVID-19 through different feeding tubes based on the patient's different needs. Initially, patients who were infected with COVID-19, including the ones who developed ventilator-dependent chronic respiratory failure, receive enteral nutrition by nasogastric tube (NGT). Also, the study ‘The Effects of Enteral Nutrition in Critically Ill Patients with COVID-19: A Systematic Review and Meta-Analysis’ conducted in the UK, reported that early enteral nutrition notably reduced the risk of mortality among critically ill patients with COVID-19. Thus, the COVID 19 had a positive impact on the enteral and parenteral medical nutrition market growth.  

A few prominent players operating in the global enteral and parenteral medical nutrition market are Abbott Laboratories, Nestle SA, Nutricia International BV, Medtrition Inc, Fresenius Kabi AG, B. Braun SE, Smartfish AS, Nutrisens SAS, AYMES International Ltd, Medifood International SA, Easy Line Ltd, Charing Cross Scientific AS, Baxter International Inc, and Medica Nutrition Inc among others. 

Companies are launching new and innovative products and services to sustain their position in the global enteral and parenteral medical nutrition market size. In November 2021, Abbott Launched Similac 360 Total Care to Support the Immune System, Digestive Health and Brain Development. Similac 360 Total Care is the first and only infant formula in the U.S. with a blend of five different HMOs, previously only found together in breast milk. This formula is designed to provide nutrition to support the whole baby’s health and development, including the developing immune system, digestive system and brain. 

The report segments the global enteral and parenteral medical nutrition market as follows:

Based on indication, the enteral and parenteral medical nutrition market is segmented into elderly, gastrointestinal disorders, diabetes, cancer, respiratory disorder, Alzheimer’s disease, dementia, renal disease, liver failure, post COVID-19, and others. Based on nutrition type, the enteral and parenteral medical nutrition market is segmented into supplemental and sole-source. By form, the enteral and parenteral medical nutrition market is segmented into liquid, powder, and semi-solid. By product type, the market is bifurcated into general and disease-specific. By route of administration, the enteral and parenteral medical nutrition market is segmented into oral, tube feed, and parenteral. By age group, the enteral and parenteral medical nutrition market is segmented into above 60 years, 18–60 years, 3–18 years, and below 3 years. By distribution channel, the enteral and parenteral medical nutrition market is segmented into hospital pharmacies, retails stores, e-commerce, and others. By geography, the enteral and parenteral medical nutrition market is segmented into North America (US, Canada, and Mexico), Europe (France, Germany, UK, Spain, Italy, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and Rest of Asia Pacific), Middle East & Africa (Saudi Arabia, UAE, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America). 

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com